$ACET
Adicet Bio, Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023019700 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.528M $6.566M
YoY Change -0.02% -3.46%
% of Gross Profit
Research & Development $28.36M $26.76M
YoY Change 75.31% 98.44%
% of Gross Profit
Depreciation & Amortization $1.510M $1.254M
YoY Change 272.84% 256.25%
% of Gross Profit
Operating Expenses $34.89M $33.32M
YoY Change 53.65% 64.28%
Operating Profit -$34.89M -$33.32M
YoY Change 53.65% -808.07%
Interest Expense $4.000K $19.00K
YoY Change -98.7% 5.56%
% of Operating Profit
Other Income/Expense, Net -$124.0K -$206.0K
YoY Change -10.14% 101.96%
Pretax Income -$32.40M -$30.88M
YoY Change 43.77% -768.71%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$32.40M -$30.88M
YoY Change 43.77% -768.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$0.72
Diluted Earnings Per Share -$0.75 -$0.72
COMMON SHARES
Basic Shares Outstanding 42.96M 42.95M
Diluted Shares Outstanding 42.96M 42.96M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $205.5M $231.6M
YoY Change -21.17% -16.64%
Cash & Equivalents $205.5M $231.6M
Short-Term Investments
Other Short-Term Assets $489.0K $511.0K
YoY Change -85.81% 1035.56%
Inventory
Prepaid Expenses $389.0K $445.0K
Receivables
Other Receivables
Total Short-Term Assets $208.7M $234.8M
YoY Change -20.99% -16.6%
LONG-TERM ASSETS
Property, Plant & Equipment $29.58M $29.89M
YoY Change -33.63% 68.5%
Goodwill $19.46M $19.46M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.005M $1.110M
YoY Change -43.82% -40.26%
Total Long-Term Assets $68.98M $70.17M
YoY Change 4.8% 19.09%
TOTAL ASSETS
Total Short-Term Assets $208.7M $234.8M
Total Long-Term Assets $68.98M $70.17M
Total Assets $277.6M $305.0M
YoY Change -15.84% -10.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.121M $2.747M
YoY Change -24.72% -20.72%
Accrued Expenses $15.72M $15.35M
YoY Change 28.29% 121.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.84M $18.10M
YoY Change 14.89% 73.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $130.0K $116.0K
YoY Change -99.36% 0.87%
Total Long-Term Liabilities $130.0K $116.0K
YoY Change -99.36% 0.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.84M $18.10M
Total Long-Term Liabilities $130.0K $116.0K
Total Liabilities $38.57M $38.76M
YoY Change 5.28% 31.98%
SHAREHOLDERS EQUITY
Retained Earnings -$301.4M -$269.0M
YoY Change 64.32%
Common Stock $540.5M $535.2M
YoY Change 12.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $239.1M $266.2M
YoY Change
Total Liabilities & Shareholders Equity $277.6M $305.0M
YoY Change -15.84% -10.42%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$32.40M -$30.88M
YoY Change 43.77% -768.71%
Depreciation, Depletion And Amortization $1.510M $1.254M
YoY Change 272.84% 256.25%
Cash From Operating Activities -$24.90M -$24.09M
YoY Change 69.32% -686.94%
INVESTING ACTIVITIES
Capital Expenditures $1.507M $1.915M
YoY Change -152.9% -27.24%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.507M -$1.915M
YoY Change -47.1% -27.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 226.0K -7.000K
YoY Change 38.65% -99.38%
NET CHANGE
Cash From Operating Activities -24.90M -24.09M
Cash From Investing Activities -1.507M -1.915M
Cash From Financing Activities 226.0K -7.000K
Net Change In Cash -26.18M -26.02M
YoY Change 50.54% -7774.34%
FREE CASH FLOW
Cash From Operating Activities -$24.90M -$24.09M
Capital Expenditures $1.507M $1.915M
Free Cash Flow -$26.41M -$26.01M
YoY Change 122.72% -1865.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001720580
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-38359
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Adicet Bio, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3305277
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
200 Berkeley Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
19th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02116
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
503-9095
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
ACET
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42957586
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
231640000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
257656000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3168000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3382000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
234808000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261038000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29886000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28710000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19708000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20269000
CY2023Q1 us-gaap Goodwill
Goodwill
19462000
CY2022Q4 us-gaap Goodwill
Goodwill
19462000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1110000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1211000
CY2023Q1 us-gaap Assets
Assets
304974000
CY2022Q4 us-gaap Assets
Assets
330690000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2747000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4404000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12399000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12811000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2949000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2492000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18095000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19707000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20548000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18531000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
116000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
114000
CY2023Q1 us-gaap Liabilities
Liabilities
38759000
CY2022Q4 us-gaap Liabilities
Liabilities
38352000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42957431
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42957431
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42954820
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42954820
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
535206000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
530448000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-268995000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238114000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
266215000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
292338000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
304974000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
330690000
CY2023Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
24990000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26756000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13483000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6566000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6801000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
33322000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
20284000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-33322000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4706000
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
2666000
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
32000
CY2023Q1 us-gaap Interest Expense
InterestExpense
19000
CY2022Q1 us-gaap Interest Expense
InterestExpense
18000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-206000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-102000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30881000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4618000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30881000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
4618000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42955688
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39823246
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42955688
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45958941
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
292338000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4765000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-30881000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
266215000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
303129000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
93000
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1106000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4350000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
4618000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
311084000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30881000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
4618000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1254000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
352000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
561000
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
645000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4765000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4350000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-18000
CY2023Q1 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
17000
CY2022Q1 acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
18000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-185000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-84000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-117000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2333000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-612000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4805000
CY2023Q1 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2474000
CY2022Q1 acet Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-361000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-249000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1497000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24094000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4105000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1915000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2632000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1915000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2632000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
94000
CY2023Q1 acet Taxes Withheld And Paid Related To Net Share Settlement Of Equity Awards
TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
-10000
CY2022Q1 acet Taxes Withheld And Paid Related To Net Share Settlement Of Equity Awards
TaxesWithheldAndPaidRelatedToNetShareSettlementOfEquityAwards
-1106000
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
122000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1134000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26016000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
339000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
257656000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277694000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231640000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278033000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
231640000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
277883000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
231640000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278033000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1081000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1481000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents. The Company’s cash and cash equivalents are held at one financial institution in the U.S. and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents in money market funds. The Company limits its credit risk associated with cash equivalents by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents to date.</span></p>
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
974000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1251000
CY2023Q1 acet Prepaid Software Subscription And Licensing Fees
PrepaidSoftwareSubscriptionAndLicensingFees
297000
CY2022Q4 acet Prepaid Software Subscription And Licensing Fees
PrepaidSoftwareSubscriptionAndLicensingFees
529000
CY2023Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
567000
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
435000
CY2023Q1 acet Prepayments To Cros
PrepaymentsToCros
273000
CY2022Q4 acet Prepayments To Cros
PrepaymentsToCros
427000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
445000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295000
CY2023Q1 acet Prepayments To Cmos
PrepaymentsToCmos
101000
CY2022Q4 acet Prepayments To Cmos
PrepaymentsToCmos
65000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
511000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
380000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3168000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3382000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
39892000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37463000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10006000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8753000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29886000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28710000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1300000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2023Q1 us-gaap Increase Decrease In Construction Payables
IncreaseDecreaseInConstructionPayables
7500000
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1800000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3755000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5703000
CY2023Q1 acet Accrued Cmo Costs
AccruedCmoCosts
5136000
CY2022Q4 acet Accrued Cmo Costs
AccruedCmoCosts
4390000
CY2023Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1197000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1356000
CY2023Q1 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
519000
CY2022Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
674000
CY2023Q1 acet Accrued Cro Costs
AccruedCroCosts
1720000
CY2022Q4 acet Accrued Cro Costs
AccruedCroCosts
657000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
72000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12399000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12811000
CY2023Q1 acet Available Under The Loan Agreement
AvailableUnderTheLoanAgreement
10600000
CY2023Q1 acet License Agreement Termination Description
LicenseAgreementTerminationDescription
twelve (12) years
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1000000.0
CY2021Q3 acet Area Of Sublease
AreaOfSublease
9501
CY2023Q1 acet Operating Leases Future Minimum Sublease Income Due Current
OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
531000
CY2023Q1 acet Operating Leases Future Minimum Sublease Income Due In Two Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
722000
CY2023Q1 acet Operating Leases Future Minimum Sublease Income Due In Three Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
736000
CY2023Q1 acet Operating Leases Future Minimum Sublease Income Due In Four Years
OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears
438000
CY2023Q1 acet Operating Leases Future Minimum Sublease Income Due
OperatingLeasesFutureMinimumSubleaseIncomeDue
2427000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3597000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
5005000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4650000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3999000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
12059000
CY2023Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
29310000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5813000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
23497000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2949000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20548000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1141000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
48000
CY2023Q1 us-gaap Sublease Income
SubleaseIncome
179000
CY2023Q1 us-gaap Lease Cost
LeaseCost
1010000
CY2023Q1 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
2474000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12417435
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9272305
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4765000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4350000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6203020
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.44
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
780000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2117400
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.06
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
713
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.76
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
178112
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.82
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8141595
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.82
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
143000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2671676
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.15
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
143000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8141595
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.82
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
143000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8325
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8619
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.774
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.777
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0355
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30881000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4618000
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
42955688
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
39823246
CY2023Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
42955688
CY2022Q1 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
45958941
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10

Files In Submission

Name View Source Status
acet-20230331_cal.xml Edgar Link unprocessable
acet-20230331_def.xml Edgar Link unprocessable
0000950170-23-019700-index-headers.html Edgar Link pending
0000950170-23-019700-index.html Edgar Link pending
0000950170-23-019700.txt Edgar Link pending
0000950170-23-019700-xbrl.zip Edgar Link pending
acet-20230331.htm Edgar Link pending
acet-20230331.xsd Edgar Link pending
acet-ex10_2.htm Edgar Link pending
acet-ex31_1.htm Edgar Link pending
acet-ex31_2.htm Edgar Link pending
acet-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
acet-20230331_pre.xml Edgar Link unprocessable
acet-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acet-20230331_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending